Esperion Therapeutics | Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
AbbVie USD 3.89B 325M 2025-12
Alnylam Pharmaceuticals USD 262.59M 60.72M 2025-09
Alterity Therapeutics Limited AUD 2.29M 649.1K 2023-06
Amarin USD 17.94M 17.86M 2025-09
Amgen USD 1.94B 237M 2025-12
Biogen USD 545.2M 38.6M 2025-09
BioMarin Pharmaceutical USD 223.42M 8.86M 2025-09
Cipla INR 13.25B 101.8M 2025-12
CSL USD 727M 453M 2025-06
Cytokinetics USD 158.75M 93.03M 2025-09
Daiichi Sankyo JPY 228.23B 39.15B 2025-12
Eli Lilly USD 3.13B 391.3M 2025-12
Esperion Therapeutics USD 39.98M 4.21M 2024-09
Geron USD 39M 437K 2025-09
Grifols EUR 333.1M 157M 2025-09
Halozyme Therapeutics USD 37.53M 4.53M 2025-09
Heron Therapeutics USD 23.34M 4.18M 2024-09
Ionis Pharmaceuticals USD 86.56M 4.04M 2025-09
Merck USD 2.85B 215M 2025-12
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Moderna USD 268M 38M 2025-09
Nektar Therapeutics USD -0.18 0.07 2024-09
Pfizer USD 4.08B 894M 2025-12
PTC Therapeutics USD 84.05M 1.22M 2025-09
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Sanofi EUR 2.75B 455M 2025-12
Sarepta Therapeutics USD 77.11M 7.22M 2025-09
United Therapeutics USD 152M 60.5M 2025-09
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12


Esperion Therapeutics Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Feb 2026.